FREA Stock Chart & Stats
€11.60
-€0.05(-0.59%)
At close: 4:00 PM EST
€11.60
-€0.05(-0.59%)
Day’s Range― - ―
52-Week Range€8.60 - €20.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€24.42B
Enterprise Value€40.89K
Total Cash (Recent Filing)€2.06B
Total Debt (Recent Filing)€11.92B
Price to Earnings (P/E)16.5
Beta0.89
Next Earnings
Aug 05, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding2,252,949,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)5.76
Price to Sales (P/S)5.00
P/FCF Ratio95.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.89
Revenue Forecast (FY)€23.94B
Bulls Say, Bears Say
Bulls Say
Diversified Healthcare Business ModelFresenius' portfolio spans dialysis services, hospital operations, clinical nutrition, infusion therapies and devices, creating multiple regulated revenue streams. This structural diversification lowers single-market risk and supports steadier consolidated revenues and cash flows over several months to years.
Improving Recent Profitability TrendsTrailing improvements in revenue growth and operating margins signal recovering operating leverage after prior weakness. Sustained mid-single-digit net margins and near-double-digit EBIT create a firmer earnings base that can support reinvestment, dividend capacity and gradual deleveraging over the medium term.
Leverage And Cash Generation ImprovingBalance-sheet repair and a meaningful TTM free cash flow rebound improve financial flexibility. A debt-to-equity around 0.6 reduces refinancing strain, enabling capital allocation for operations, M&A or dividends and providing a stronger buffer versus cyclical shocks in coming quarters.
Bears Say
Earnings Volatility And Prior LossHistory of sizable profit swings and a recent year with a loss undermines predictability of earnings and cash flow. That cyclicality complicates multi-quarter planning, raises forecasting risk for margins and cash conversion, and limits confidence in sustained improvement absent clearer stability.
Uneven Cash-flow ConversionAlthough TTM FCF rose, inconsistent cash generation and modest OCF-to-revenue (~0.31) limit reliable internal funding for capex, dividends, or debt reduction. Year-to-year swings imply sensitivity to working capital and operational swings that could constrain strategic moves over coming quarters.
Mid-range Returns On CapitalROE and margins remain moderate relative to capital intensity, limiting capacity to self-fund rapid growth or absorb margin pressure. Sustained mid-single-digit returns imply the company needs efficiency gains or higher-margin mix shifts to materially improve long-term profitability and competitive positioning.
Fresenius SE & Co News
FREA FAQ
What was Fresenius SE & Co’s price range in the past 12 months?
Fresenius SE & Co lowest stock price was €8.60 and its highest was €20.00 in the past 12 months.
What is Fresenius SE & Co’s market cap?
Fresenius SE & Co’s market cap is €24.42B.
When is Fresenius SE & Co’s upcoming earnings report date?
Fresenius SE & Co’s upcoming earnings report date is Aug 05, 2026 which is in 11 days.
How were Fresenius SE & Co’s earnings last quarter?
Fresenius SE & Co released its earnings results on May 06, 2026. The company reported €0.212 earnings per share for the quarter, missing the consensus estimate of €0.222 by -€0.011.
Is Fresenius SE & Co overvalued?
According to Wall Street analysts Fresenius SE & Co’s price is currently Overvalued.
Does Fresenius SE & Co pay dividends?
Fresenius SE & Co does not currently pay dividends.
What is Fresenius SE & Co’s EPS estimate?
Fresenius SE & Co’s EPS estimate is 0.22.
How many shares outstanding does Fresenius SE & Co have?
Fresenius SE & Co has 2,252,949,200 shares outstanding.
What happened to Fresenius SE & Co’s price movement after its last earnings report?
Fresenius SE & Co reported an EPS of €0.212 in its last earnings report, missing expectations of €0.222. Following the earnings report the stock price went down -0.507%.
Which hedge fund is a major shareholder of Fresenius SE & Co?
Currently, no hedge funds are holding shares in DE:FREA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius SE & Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:FREA Sentiment 70%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.93%
12-Months-Change
Fundamentals
Return on Equity
2.47%
Trailing 12-Months
Asset Growth
4.60%
Trailing 12-Months
Company Description
Fresenius SE & Co
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment caters to individuals with renal diseases. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany.
Technical Analysis
DaVita
―
Fresenius Medical Care
―
HCA Healthcare
―
Tenet Healthcare
―
Universal Health
―